Fusigen Reduces Intracellular Reactive Oxygen Species and Nitric Oxide Levels.
A. melanogenum
Siderophore
fusigen
nitric oxide
reactive oxygen species
Journal
In vivo (Athens, Greece)
ISSN: 1791-7549
Titre abrégé: In Vivo
Pays: Greece
ID NLM: 8806809
Informations de publication
Date de publication:
Historique:
received:
26
12
2018
revised:
15
01
2019
accepted:
16
01
2019
entrez:
27
2
2019
pubmed:
26
2
2019
medline:
6
6
2019
Statut:
ppublish
Résumé
Oxidative stress caused by the production of excessive cellular reactive oxygen species (ROS) and high levels of nitric oxide contribute to several human pathologies. This study aimed to examine the anti-oxidant effects of fusigen, a compound produced from Aureobasidium melanogenum. Extracts of A. melanogenum were selected as a source for the isolation of fusigen. The anti-oxidant, nitric oxide suppression, as well as the free radical scavenging activities of fusigen were tested in BEAS-2B human bronchial epithelial cell line (BEAS-2B cells) and human dermal papilla cells (DP cells) using specific fluorescence dyes and flow cytometry analysis. Cell viability was determined by the MTT assay. Fusigen did not exert cytotoxicity in the human normal BEAS-2B and DP cells at concentrations up to 100 μM. Fusigen decreased basal levels of cellular ROS, as well as the levels of ROS induced by hydrogen peroxide and ferrous ion enrichment. ROS decreasing effect was confirmed in DP cells. In addition, fusigen treatment suppressed intracellular NO levels in both BEAS-2B and DP cells. The optimal process of production of purified fusigen from A. melanogenum was determined. Fusigen exhibited a low cytotoxic effect and the potential to suppress ROS and NO. These results demonstrated that fusigen may be used for the treatment or prevention of human diseases.
Sections du résumé
BACKGROUND/AIM
OBJECTIVE
Oxidative stress caused by the production of excessive cellular reactive oxygen species (ROS) and high levels of nitric oxide contribute to several human pathologies. This study aimed to examine the anti-oxidant effects of fusigen, a compound produced from Aureobasidium melanogenum.
MATERIALS AND METHODS
METHODS
Extracts of A. melanogenum were selected as a source for the isolation of fusigen. The anti-oxidant, nitric oxide suppression, as well as the free radical scavenging activities of fusigen were tested in BEAS-2B human bronchial epithelial cell line (BEAS-2B cells) and human dermal papilla cells (DP cells) using specific fluorescence dyes and flow cytometry analysis. Cell viability was determined by the MTT assay.
RESULTS
RESULTS
Fusigen did not exert cytotoxicity in the human normal BEAS-2B and DP cells at concentrations up to 100 μM. Fusigen decreased basal levels of cellular ROS, as well as the levels of ROS induced by hydrogen peroxide and ferrous ion enrichment. ROS decreasing effect was confirmed in DP cells. In addition, fusigen treatment suppressed intracellular NO levels in both BEAS-2B and DP cells.
CONCLUSION
CONCLUSIONS
The optimal process of production of purified fusigen from A. melanogenum was determined. Fusigen exhibited a low cytotoxic effect and the potential to suppress ROS and NO. These results demonstrated that fusigen may be used for the treatment or prevention of human diseases.
Identifiants
pubmed: 30804121
pii: 33/2/425
doi: 10.21873/invivo.11490
pmc: PMC6506322
doi:
Substances chimiques
Ferric Compounds
0
Hydroxamic Acids
0
Reactive Oxygen Species
0
fusigen
19624-79-4
Nitric Oxide
31C4KY9ESH
Hydrogen Peroxide
BBX060AN9V
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
425-432Informations de copyright
Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
Références
Ross Fiziol Zh Im I M Sechenova. 1998 Dec;84(12):1420-7
pubmed: 10204189
Cancer Lett. 2005 Jan 31;218(1):1-14
pubmed: 15639335
J Ren Nutr. 2005 Jan;15(1):105-10
pubmed: 15648017
Int Heart J. 2005 Mar;46(2):255-64
pubmed: 15876809
J Carcinog. 2006 May 11;5:14
pubmed: 16689993
Cancer Res. 1991 Jan 1;51(1):349-53
pubmed: 1670992
Kidney Int. 2007 Sep;72(5):557-65
pubmed: 17538569
Bioresour Technol. 2009 May;100(9):2639-41
pubmed: 19162476
Biometals. 2009 Dec;22(6):965-72
pubmed: 19459055
Nat Prod Rep. 2010 May;27(5):637-57
pubmed: 20376388
J Alzheimers Dis. 2010;20 Suppl 2:S357-67
pubmed: 20421690
Free Radic Biol Med. 2010 Dec 1;49(11):1603-16
pubmed: 20840865
J Pathol Bacteriol. 1946 Apr;58:207-12
pubmed: 20996420
Free Radic Biol Med. 2011 Jul 1;51(1):17-29
pubmed: 21549190
Methods Enzymol. 1990;186:1-85
pubmed: 2172697
Oxid Med Cell Longev. 2011;2011:809696
pubmed: 21904647
Free Radic Res. 2012 Apr;46(4):382-419
pubmed: 22276778
Oxid Med Cell Longev. 2012;2012:428010
pubmed: 22685618
Oxid Med Cell Longev. 2013;2013:316523
pubmed: 23983897
BMC Genomics. 2014 Jul 01;15:549
pubmed: 24984952
Nat Prod Rep. 2014 Oct;31(10):1266-76
pubmed: 25140791
Exp Neurobiol. 2015 Dec;24(4):325-40
pubmed: 26713080
Toxicol Rep. 2015 May 11;2:721-728
pubmed: 28962407
Folia Microbiol (Praha). 2018 Mar;63(2):129-140
pubmed: 29079936
Eur J Biochem. 1967 Dec;3(2):213-8
pubmed: 6082611
Science. 1983 Sep 23;221(4617):1256-64
pubmed: 6351251
Cardiovasc Res. 1994 Jan;28(1):34-9
pubmed: 7509259
J Biol Chem. 1995 Nov 10;270(45):26723-6
pubmed: 7592901
Environ Health Perspect. 1994 Dec;102 Suppl 10:17-24
pubmed: 7705293
Clin Exp Metastasis. 1995 Jan;13(1):16-22
pubmed: 7820952
Thromb Res. 1994 Aug 1;75(3):329-35
pubmed: 7992244
Crit Care Med. 1993 Sep;21(9):1287-95
pubmed: 8370291
Toxicol Lett. 1995 Dec;82-83:969-74
pubmed: 8597169
Gut. 1998 Mar;42(3):313-4
pubmed: 9577329